Fund moves

Edwards Lifesciences (EW): Jacobs Levy Equity Management, Inc reduced its stake -161K shares

Jacobs Levy Equity Management, Inc reduced its stake in Edwards Lifesciences, per its Q2 2026 13F.

2.77M
Shares reported · -161K vs prior quarter
0.90%
Disclosed portfolio weight
$251M
Reported value
Holdings as of
Jun 30, 2026
Filed
Aug 14, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 27, 2026CongressDisclosed purchase of EW — reported range $1,001 - $15,000
  2. Jun 17, 2026InsiderCEO sold ~$46K of EW shares in the open market
  3. Jun 26, 2026FDAFDA device clearance: ECLIPTIS Left Atrial Appendage Exclusion System (ECS135); ECLIPTIS Left Atrial Appendage Exclusion System (ECS140); ECLIPTIS Left Atrial Appendage Exclusion Sy…
  4. Jun 30, 2026InsiderOfficer sold ~$57K of EW shares in the open market
  5. Jul 10, 2026InsiderOfficer sold ~$57K of EW shares in the open market
  6. Jul 23, 2026Company filing · Form 8-K · ResultsReported its results
  7. Jul 23, 2026Government · Federal Register noticeUnited States v. Edwards LifeSciences Corp. and Genesis MedTech Group Limited; Proposed Final Judgment and Competitive Impact Statement
  8. Jul 27, 2026InsiderCEO sold ~$245K of EW shares in the open market
  9. Jul 28, 2026InsiderOfficer sold ~$819K of EW shares in the open market
  10. Jul 30, 2026InsiderOfficer sold ~$13K of EW shares in the open market
  11. Aug 11, 2026InsiderOfficer sold ~$57K of EW shares in the open market

What came next

  1. Aug 25, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“The Board of Directors of Edwards Lifesciences Corporation, a Delaware corporation (“Edwards” or the “Company”), has received notice from Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, of his decision to retire from the Company by mid-year 2027.”
  2. Aug 26, 2026Insider · 2 peopleInsiders: 3 sales (~$3.0M)
  3. Aug 28, 2026InsiderOfficer sold ~$238K of EW shares in the open market
  4. Aug 31, 2026InsiderOfficer sold ~$50K of EW shares in the open market
  5. Sep 11, 2026InsiderOfficer sold ~$54K of EW shares in the open market
  6. Oct 1, 2026FDAFDA device approval: Autus Size-Adjustable Valve
  7. Oct 5, 2026FDARecall: Generic Name: Edwards Commander M Delivery System Generic Name: Edwards Commander M Delivery System Model/Catalog Number: 9880CM29A Software Version: Not appli…
  8. Oct 8, 2026InsiderOfficer sold ~$53K of EW shares in the open market
  9. Nov 4, 2026Company filing · Form 8-K · ResultsReported its results
  10. Nov 9, 2026Insider · 2 peopleInsiders: 3 sales (~$7.4M)
  11. Nov 10, 2026InsiderOfficer sold ~$65K of EW shares in the open market
  12. Nov 19, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Edwards Lifesciences

For Edwards Lifesciences, OQRO holds 14 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its EW page.

How this filing works

Explore the data

Common questions

What does this filing report about Edwards Lifesciences (EW) stock?

Jacobs Levy Equity Management, Inc reduced its stake in Edwards Lifesciences, per its Q2 2026 13F. Now 2.77M shares, $251M reported value, 0.90% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Jun 30, 2026. Filed: Aug 14, 2026.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Edwards Lifesciences recently?

For Edwards Lifesciences, OQRO holds 14 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the EW page.

Does this mean EW stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Edwards Lifesciences

Everything OQRO holds on this company is on its EW page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data